Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007956 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00007956: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00007956 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00007956, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have recurrent or refractory lymphoma.
Interventions
- BIOLOGICAL monoclonal antibody mono-dgA-RFB4
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007956
The ClinicalTrials.gov registry entry for NCT00007956 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody mono-dgA-RFB4 is the first listed.
NCT00007956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00007956 about?
NCT00007956 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have recurrent or refractory lymphoma.
What is the current status of trial NCT00007956?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-11.
What interventions are being tested in trial NCT00007956?
The interventions under investigation include: monoclonal antibody mono-dgA-RFB4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00007956?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.